Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use

Information

  • Patent Grant
  • 10159637
  • Patent Number
    10,159,637
  • Date Filed
    Thursday, April 19, 2018
    6 years ago
  • Date Issued
    Tuesday, December 25, 2018
    5 years ago
Abstract
An improved hair and scalp treatment composition comprising a hair care product wherein the improvement comprises reducing the comedogenicity thereof by excluding therefrom comedogenic elements having a Fulton scale grade greater than 2.
Description
BACKGROUND

When a person uses hair products on their hair, those same hair products can migrate to the skin through various mechanisms. For example, when shampooing and/or conditioning hair, the shampoo and conditioner unavoidably come into contact with the scalp, face, neck, chest, shoulders, and back, either through direct contact or as they are rinsed off and run down the skin in the shower.


Many hair care products, including rinse off products, such as shampoos and conditioners, are also designed to leave a residue even after the product is subsequently rinsed out of the hair. Leave in hair care products by design are not rinsed out and always leave a residue. This residue may be good for the hair, but can often cause problems for the skin. This residue can be deposited on the skin directly by direct contact with the skin on the scalp, and, for example, by dripping down from the hair to the face after application as well as when it runs down the person's face, neck, chest, shoulders, and/or back in the shower. This residue can also be deposited on a person's skin indirectly, when an object successively comes into contact with the person's hair, and then their skin. For example, if the person dries their hair with a towel, the residue can be transferred to other parts of their body via the towel; residue may also be transferred from a person's hair to their face from a pillowcase.


Most hair care products are developed without consideration of the impact that the product will have on the user's skin, despite the fact that contact with the skin with each use is unavoidable. Many hair care products can also build up on the skin or scalp over time, particularly if the hair care product is intended to be left in for days at a time; as a result, the hair care products may have a dramatically detrimental effect on the skin of a user. Many hair care products also contain ingredients that can trigger irritation of the skin in some users. In some cases, hair and skin treatments may also have incompatible regimens; for example, a person with parched hair strands resulting from coloration of their hair, may require hair products with significant amounts of oils and conditioning agents, some of which can be comedogenic to the skin.


According to the American Academy of Dermatology [AAD], a “comedo” is an “acne lesion”, a hard blockage created from an excess of sebum combined with keratin (skin debris) in a pore which can lead to whiteheads, blackheads and pimples. Accordingly, the term, “comedogenic”, refers to ingredients or products that have a tendency to block pores and promote comedones or acne.


Those with curly and/or frizzy hair may use smoothing products that traditionally contain ingredients such as oils and conditioning agents that can be comedogenic, or can become comedogenic in combination with other ingredients. For example, some common hair smoothing products, such as some silicone hair smoothing products, have not been found to be significantly comedogenic on their own, but have been found to increase the penetration of other ingredients in a formulation, which may result in a more comedogenic product. This means that hair care products can, in many cases, contribute to and exacerbate skin conditions such as acne (or “acne vulgaris”), the most common skin disease in the United States.


Acne vulgaris affects up to 50 million people in the United States alone. Acne is not just a condition that affects teenagers. Acne is highly prevalent in adult women, with one study showing that 45% of women aged 21-30, 26% aged 31-40, and 12% aged 41-50 had clinical acne. Adult acne in women is also on the rise. According to the American Academy of Dermatology (AAD), acne can contribute to depression, anxiety, and poor self-image. It can also leave permanent scars.


Acne may arise when hair follicles (pilosebaceous units) become clogged. Acne is characterized by comedones, clogged pores in the skin, which can either be open comedones (“blackheads”) or closed comedones (“whiteheads”). Acne is also characterized by pimples, which can appear as inflammatory papules or pustules, cysts, or nodules.


Acne is caused by several major mechanisms: inflammation, oil/sebum, follicular hyperkeratinization, propionibacterum acnes (p. acnes), a bacteria, and hormones. Sebum, an oily substance secreted by the sebaceous glands of the skin, can cause dead skin cells to stick together, which can clog pores and plug hair follicles, causing acne. Sebum secretion has been correlated with acne severity, with high sebum secretion levels tended to be correlated with more severe acne; in some cases, a high sebum secretion rate may even be the decisive factor in inflammatory acne.



P. acnes is a bacteria that lives on the skin and can also get inside the follicle and contribute to inflammation, causing inflammatory acne lesions, including papules, cysts, and nodules. Conventional belief was that all inflammatory acne lesions arose from comedones. Recently, acne has been identified to be a primary inflammatory condition. There is evidence that inflammation plays a role at all stages of acne development, and can even be observed subclincally before the formation of comedones.


Acne can also be caused or exacerbated by certain cosmetics or styling products. “Acne cosmetica” is a form of acne that is caused by or exacerbated by the use of certain cosmetic products, including, though not limited to, makeup and sunscreen. “Acne cosmetica” typically results from a chemically-induced plugging of the hair follicles by these products. Certain cosmetic products can also produce folliculitis, or inflammation of the hair follicle, which appears as small bumps on the skin that can be skin-colored, pink, or red, having an appearance similar to acne.


For example, “pomade acne” is a similar condition to “acne cosmetica,” also resulting from chemically-induced plugging of the hair follicles, and characterized by bumps on the forehead caused by oily hair care styling products. This condition was originally described primarily in African American men. Both “acne cosmetica” and “pomade acne” may also be referred to generally as “acneiform eruptions.” Pomade acne has more recently been described as being an issue in all skin types, in both men and women due to hair products that smooth the hair, add shine, and reduce frizz. These products can contain oils, and waxes that clog pores, trap bacteria, and cause inflammation. Users of these products may find that these products are transferred to their pillow at night if left in their hair; as a result, users of these products may find that their faces are rolling around in oily, waxy, hair products all night. (Other hair products, particularly products not designed to be washed out within a day or so, may also cause similar problems.)


The ingredients in these hair products that clog pores and cause acne are not limited to oils and waxes used for styling and conditioning, as other ingredients can be problematic. Comedogenic or potentially comedogenic components include PVP/DMAPA acrylates, cyclopentasiloxane, panthenol, dimethicone, some silicones (typically to a mild degree), Quaternium-70, oils, and petrolatum. These ingredients may be comedogenic themselves, or, as mentioned previously, may enhance the comedogenicity, irritation, and/or allergic potential of other ingredients. For example, petrolatum itself is non-comedogenic, but is occlusive and can trap moisture and other ingredients in the hair follicles, causing stronger reactions to these ingredients.


For patients with adult acne, the AAD recommends using personal care products, including hair care products, which have one of the following labels: “non-comedogenic,” “non-acnegenic,” “oil-free,” or “won't clog pores.” However, these labels are not typically found on hair care products because hair care products are not typically formulated to be “non-comedogenic,” “non-acnegenic,” or “oil-free.” Currently, it is not standard to test hair care products for comedogenicity or acnegenicity, or to have oil-free hair care products for acne-prone skin. In fact, there is a trend in the beauty industry to add oils to hair care products.


Many common hair care products, such as shampoos, conditioners, and other hair care products, contain oils that are or have the potential to be comedogenic. As mentioned, other products, such as silicones, can also be comedogenic in combination with other products in a formulation. Many leave-in products also contain significant quantities of these oils and silicones that can be comedogenic, including, though not limited to, styling creams, gels, pomades, hairsprays, smoothing serums, heat styling sprays, anti-frizz serums, heat-protectants, and shine sprays. Other materials in hair care products are also potentially comedogenic.


A list of comedogenic or potentially comedogenic materials includes, but is not limited to, acetylated lanolin, acetylated lanolin alcohol, algin, almond oil, apricot kernel oil, avocado oil, grapeseed oil, bismuth oxychloride, butyl stearate, carrageenan, ceteareth 20, cetyl acetate, cocoa butter, coconut oil, coal tar, hydrogenated oils, D & C Red #17, D & C Red #21, D & C Red #3, D & C Red #30, D & C Red #36, decyl oleate, disodium oleamido peg-2 sulfosuccinate, lanolin, lanolin derivatives, ethylhexyl palmitate, glyceryl stearate SE, glyceryl-3-diisostearate, hexadecyl alcohol, hydrogenated vegetable oil, isocetyl alcohol, isocetyl stearate, isodecyl oleate, isopropyl isostearate, isopropyl myristate, isopropyl palmitate, isostearyl isostearate, isostearyl neopentanoate, laureth-23, laureth-4, lauric acid, mink oil, myristic acid, myristyl lactate, myristyl myristate, octyl palmitate, octyl stearate, oleic acid, oleates, oleth-3, oleyl alcohol, olive oil, peg 200 dilaurate, PEG 8 stearate, PG monostearate, PPG 2 myristyl propionate, polyglyceryl-3-diisostearate, propylene glycol monostearate, sesame oil, sodium laureth sulfate, sodium lauryl sulfate, sorbitan oleate, soybean oil, steareth 10, stearyl heptanoate, sulfated oils, triethanolamine, wheat germ glyceride, wheat germ oil, and certain conditioning agents. Occlusive agents, including some of the above materials, can often contribute to comedogenicity and acne. See Fulton, J. Soc. Cosmet. Chem., 40, 321-333 (November/December 1989) “Comedogenicity and irritancy of commonly used ingredients in skin care products” for a discussion of comedogenic materials.


In addition, most shampoos contain potentially irritating surfactants, such as sulfate-based surfactants; for example, sodium lauryl sulfate and ammonium lauryl sulfate are common surfactants that can cause irritation. Irritation to the skin can produce folliculitis and small papules on the skin, which may appear similar to acne. The folliculitis that occurs is indistinguishable from acne to the majority of hair care product users. Irritation of the follicle can also increase penetration of other materials in the hair care product into the skin follicles, increasing the potential comedogenicity and acnegenicity of many materials that could come into contact with the skin, including other materials in the hair care product formulation.


SUMMARY

Non-comedogenic and/or non-acnegenic hair care formulations may be disclosed. In some embodiments, the hair care formulation may be any kind of hair care product, including, for example, a shampoo, conditioner, or a styling product such as a styling spray, a hair spray, a shine enhancer, a root spray, a hair masque, a gel, or a styling cream, or some combination thereof. Such a formulation may allow for the cleaning, conditioning, and/or styling of the hair of a user without causing or promoting irritation or acne on the skin of the user. Such a formulation may also help resolve skin irritation, breakouts, and/or acne.


In an exemplary embodiment, the formulation may be used as part of a two-step method for washing hair. In the first step, a non-comedogenic and/or non-acnegenic shampoo is applied to cleanse the hair, and, in the second step, a non-comedogenic and/or non-acnegenic hair conditioner may be applied.







DETAILED DESCRIPTION OF THE EMBODIMENTS

Aspects of the invention are disclosed in the following description and related drawings directed to specific embodiments of the invention. Alternate embodiments may be devised without departing from the spirit or the scope of the invention. Additionally, well-known elements of exemplary embodiments of the invention will not be described in detail or will be omitted so as not to obscure the relevant details of the invention. Further, to facilitate an understanding of the description discussion of several terms used herein follows.


The word “exemplary” is used herein to mean “serving as an example, instance, or illustration.” Any embodiment described herein as “exemplary” is not necessarily to be construed as preferred or advantageous over other embodiments. Likewise, the term “embodiments of the invention” does not require that all embodiments of the invention include the discussed feature, advantage or mode of operation.


According to an exemplary embodiment, certain hair care formulations that are non-comedogenic, or which are non-comedogenic and which do not tend to cause acne (non-acnegenic), may be disclosed. In some exemplary embodiments, such hair care formulations may prevent, improve, and/or alleviate acne, acneiform eruptions, folliculitis, pimples, blemishes, and/or skin breakouts.


According to another exemplary embodiment, methods for using the hair care formulations may be described. Such methods may be used in isolation or as part of a regimen, as may be desired. For example, in an exemplary embodiment, hair care formulations may be used in a multi-step shower method. This method may include, in step 1, applying shampoo; and, in step 2, applying conditioner. In some exemplary embodiments, hair care products may be used as part of a method for using a hair care formulation, or may be used independently, as desired. These products, or other products (such as shampoo, conditioner, and styling product) may be sold as part of a kit and designed to be compatible with or to complement one another, as may be desired.


As mentioned, a variety of causes for acne can exist, including follicular hyperkeratinization (keratinocytes stick together and block the pore), inflammation, sebum, propionibacterium acnes, hormones, and other factors. Therefore, an exemplary embodiment of a non-comedogenic or non-acnegenic hair care product may include a keratinolytic agent, an anti-inflammatory agent, a sebum modulator, and/or antimicrobial agents, as well as other ingredients or additives, as desired. In some exemplary formulations, only one or more of the above components may be added; for example, in an exemplary embodiment, an anti-inflammatory agent may be added, but a keratinolytic agent, sebum modulator, or antimicrobial agent may not be added. Other combinations may also be envisioned, as desired.


According to an exemplary embodiment, a keratinolytic agent may be added to the composition, and may, for example, be used to modulate and correct abnormal follicular keratinization. This may help to prevent obstruction of the hair follicle and subsequent bacterial overgrowth. Exemplary keratinolytic agents that may be used in the formulation include willowbark (salicin) or bakuchiol. In other exemplary embodiments, as discussed above, a keratinolytic agent may not be present.


According to an exemplary embodiment, an anti-inflammatory agent may be added to the composition and may, for example, be used to reduce skin inflammation, therefore preventing and/or improving acne lesions, including comedones, papules, cysts, and nodules. Exemplary anti-inflammatory agents that may be used in the formulation include bisabolol (an anti-inflammatory chamomile derivative), stearyl glycyrrhetinate, or grapefruit seed extract (Citrus Grandis seed extract). Exemplary anti-irritant agents that may be used in the formulation include pea protein.


According to an exemplary embodiment, a sebum modulator may be added to the composition and may, for example, be used to control the amount of sebum secreted by the sebaceous glands of the skin. Clinically, measures to decrease sebum have been shown to improve acne. For example, both systemic and topical treatments may be available. An exemplary embodiment of a formulation may make use of one or more topical sebum modulators, as desired. Systemic retinoids, including isotretinoin, reduce sebum, and are one of the most powerful acne treatments available, but generally must be administered orally; as such, an exemplary embodiment of a formulation may be formulated to be compatible with a simultaneous systemic retinoid treatment or other oral or topical acne treatment of a patient, if desired. Exemplary sebum modulators that may be used in the formulation include Farnesyl Acetate, Panthenyl Triacetate, Tocopheryl Acetate, or grapefruit seed extract (Citrus Grandis seed extract). In other exemplary embodiments, as discussed above, a sebum modulator may not be present. An exemplary embodiment of a formulation may also be formulated to be compatible with a separate topical acne treatment regimen, if desired.


According to an exemplary embodiment, other ingredients or additives may be added to the formulation. These may serve a variety of purposes, or may serve multiple purposes. For example, exemplary additives may be added for the purpose of protecting against pollution or protecting against ultraviolet light (UV), or for other purposes, as may be desired. Exemplary multifunction additives that may be added to the formulation include algae extract, juice pressed from blackcurrant and raspberry leaves, butyl avocadate, zinc PCA, epilobium fleischeri extract, Laminaria Cloustoni extract, grapefruit seed extract (Citrus Grandis seed extract), or Moringa oleifera seed extract (horse-radish tree). However, in other exemplary embodiments, no multifunction additives may be added to the formulation, as may be desired.


According to an exemplary embodiment, if desired, one or more high molecular weight ingredients may be added to the formulation. For example, according to an exemplary embodiment, a large constituent such as a polymer of polyethylene glycol (PEG) may be added to the formulation. This may serve to reduce the comedogenicity of the overall formulation.


According to an exemplary embodiment, if desired, one or more of a polar sugar or a heavy metal may be added to the formulation to reduce the comedogenicity of the overall formulation. For example, according to an exemplary embodiment, zinc may be added to the formulation.


According to an exemplary embodiment, the degree of etholxylation of one or more of the molecules used in the formulation may be increased, or one or more ethoxylated materials may be added.


According to an exemplary embodiment, ingredients which are known to be comedogenic or which are potentially comedogenic, may be excluded from the formulation. For example, in an exemplary embodiment, the formulation may be oil-free, and free of laureth-4, isopropyl myristate and its analogs, lanolins, waxes, and certain conditioning agents, as well as other comedogenic or acnegenic compounds or compositions listed above or in a previous section. Occlusive agents, such as some of the above materials, can often contribute to comedogenicity and acne. In an embodiment, ingredients which are known to be irritating or potentially irritating, or ingredients that function as common allergens or which are not known to be hypoallergenic, may also be excluded from the formulation. For example, according to an exemplary embodiment, the formulation may be sulfate-free. In some embodiments, ingredients that can exacerbate the comedogenic or acnegenic properties of another ingredient but which do not themselves have significant comedogenic or acnegenic properties, such as silicone, may also be excluded. For example, in some exemplary embodiments, a silicone substitute, such as hemisqualane (a non comedogenic silicone substitute that has skin benefits) may be substituted for silicone in some quantity. In some other exemplary embodiments, silicone or another ingredient that can exacerbate the comedogenic or acnegenic effects of another ingredient may be included, and the comedogenic and acnegenic properties of the formulation may be controlled by controlling other ingredients of the formulation instead.


In an exemplary embodiment, ingredients which are known to be comedogenic or which are known to potentially be comedogenic when present in a formulation at a particular level may be kept below the level at which they are comedogenic. For example, according to an exemplary embodiment, a non-comedogenic conditioner may be provided by reducing but not eliminating the quantity of cetearyl alcohol present in a formulation; cetearyl alcohol may be comedogenic in high concentrations and minimally reactive at low concentrations.


In some embodiments, the products will also be paraben-free, formaldehyde-free, and phthalate-free, or may not have any of those components in any significant quantities.


Generally, those ingredients with a Fulton scale grade [Fulton, J. Soc. Cosmet. Chem., 40, 321-333 (November/December 1989) “Comedogenicity and irritancy of commonly used ingredients in skin care products”] of greater than about 2 may be excluded from the compositions of the invention.


In an exemplary embodiment, the pH of the formulation may be controlled at a desirable level, which may serve to reduce irritation and inflammation. It may be understood that the skin of a typical person is slightly acidic, typically having a pH of around 5.5 to 6.5, whereas many soaps, particularly bar soaps, may be formulated to have a pH that is slightly basic (around 8 to 9). This may cause skin irritation and inflammation. According to an exemplary embodiment, one or more acids may be added to the formulation such that the formulation has a pH that is neutral or slightly acidic, as desired. In some exemplary embodiments, different optimal ranges may be targeted for different non-comedogenic and/or non-acnegenic hair care formulations; for example, in an exemplary embodiment, the optimal pH of the shampoo may be 5.5-6.5 and the optimal pH of the conditioner may be 4.8-5.3. In other exemplary embodiments, pH may be controlled at another level, if desired; in other exemplary embodiments, no additives may be added to the composition in order to control pH.


In another exemplary embodiment, the composition may also be formulated to have desirable qualities as a hair care product. For example, according to an exemplary embodiment, the composition may be rinseable and designed to leave only skin-friendly residue when rinsed. This may further minimize the potential for irritation or comedogenicity from the product. The rinseability of the product may also provide other benefits, such as other benefits to the skin, such as may be desired. In another exemplary embodiment, the composition may be formulated to be color-safe or may otherwise be formulated to have minimal impact on color-treated hair.


According to an exemplary embodiment, variations of the composition may be formulated for use in specialized hair care products. In an exemplary embodiment, stratification between said hair care products may be based on hair type, benefit, or intended customer. For example, according to an exemplary embodiment, variations of an exemplary composition may be prepared specifically for and marketed at women, men, teens, and others. In an exemplary embodiment, variations of an exemplary composition may be prepared specifically for curly hair, damaged hair, dry hair, fine or flat hair, as well as more typical or normal hair. In an exemplary embodiment, variations of an exemplary composition may be prepared specifically for anti-frizzing, for promoting shine, for smoothing hair, for strengthening hair, or for any other purposes as may be desired.


An exemplary formulation of a hair care product formulated to have non-comedogenic and/or non-acnegenic properties may be disclosed in table 1 and may be made by combining the following components in the proportions stated below. In an exemplary embodiment, the hair care product in table 1 may be used as a shampoo.









TABLE 1







Non-Comedogenic/Acnegenic


Shampoo Exemplary Compositions











Ingredient
Broad %
Preferred





Part A
Water
10.0-70.0
20.0-40.0



Disodium EDTA
0.00-1.00
0.01-0.20


Part B
Glycerin
0.00-10.0
0.01-3.00



Guar Hydroxypropyltrimonium
0.05-5.00
0.01-0.50



chloride




Part C
Citric acid
0.00-2.00
0.01-1.00


Part D
Phenoxyethanol
0.01-1.00
0.01-1.00



Ethylhexylglycerin
0.01-1.00
0.01-0.50



Polyquaternium-7
0.50-10.0
0.50-5.00



Sodium lauroyl methyl
10.0-70.0
30.0-60.0



isethionate





Cocamidopropylamine oxide
1.00-20.0
5.00-10.0



Glycol distearate
0.00-10.0
0.50-1.00


Part E
Water
0.00-8.00
2.00-8.00



Acrylates copolymer
1.00-15.0
2.00-6.00


Part F
C13-C15 alkane
0.01-10.0
0.01-1.50



Bisabolol
0.01-1.00
0.01-0.50



Fragrance
0.00-3.00
0.01-1.00



Aminomethyl propanol
0.01-5.00
0.01-1.00









In exemplary embodiments, the components of a chemical composition provided under a trade name may be used instead of the composition provided under the trade name. For example, according to an exemplary embodiment, an exemplary formulation of hair care product may include phenoxyethanol and ethylhexylglycerin as separate components rather than including Euxyl PE 9010. This may allow the component chemicals (such as, again, phenoxyethanol and ethylhexylglycerin) to be provided in different proportions than are found in the chemical composition provided under the trade name. The acrylates copolymer listed in table 1 may be that sold under the trade name, Carbopol Aqua SF-1; however, it will be understood by those skilled in the art that any suitable lightly cross-linked rheology modifying acrylate copolymer may be employed in the practice of the invention.


According to an exemplary embodiment, an exemplary hair care product formulation of table 1 may be prepared according to the following process or a process similar to the following. In a first step, a sanitized mixing vessel may be prepared, and a quantity of deionized water may be added to the sanitized mixing vessel. The remaining components of Part A, which in the exemplary case shown in table 2 may be Disodium EDTA, may then be mixed into the mixing vessel.


In a next step, the ingredients of part B may be premixed and may then be added to the batch. The ingredients may be mixed into the batch until the batch is uniform. The ingredients of part C may then be added to the combined batch, and again mixed until the resulting batch is completely smooth.


The combined parts A, B, and C may then be heated. For example, according to an exemplary embodiment, the combined batch may be heated to a temperature within a range of 60 to 65° C.


The ingredients of Part D may then be added. The resulting batch may be mixed until all solids are melted and the batch is uniform. Once the batch has been fully mixed, the batch may be cooled to a temperature within a range of 40 to 45° C.


Once the batch has been cooled to a temperature within a range of 40 to 45° C., the parts of part E may be added. The components of part E may be pre-mixed prior to addition, which may be done, for example, concurrently with another step preceding the addition of components in part E. Once the parts of part E have been added, the resulting batch may be mixed until uniform.


Once the resulting batch has been mixed until uniform, the ingredients of part F may be added, and likewise mixed until uniform. The batch may then be cooled to a temperature of approximately 35° C. According to an exemplary embodiment, the pH of the batch may at this time be adjusted to a pH within a range of 6.50 to 6.75.


The resulting composition may be a hair care product having the appearance of semi-viscous pearlized gel. The color may be pearlescent white to off-white, which may in some exemplary embodiments be adjusted if desired. The odor may be characteristic of the fragrance added to the composition; in some exemplary embodiments, the fragrance may be reduced or left out of the composition in order to produce an odorless composition. In an exemplary embodiment, the composition may have a pH at 25° C. of between 6.5 and 7.0, a viscosity at 25° C. (RVT), at spindle 5 at 20 rpm, of between 1000 and 12,000 cPs, and a specific gravity at 25° C. of between 0.98 and 1.03. In an exemplary embodiment, the composition may be kept to a low level of viable bacterial or fungal cells or other colony-forming units (CFU), of approximately <10 CFU/g; the composition may also be kept free of pathogens.


According to an exemplary embodiment, in a production environment, one or more small-scale batches, such as lab or pilot batches, may be made prior to large-scale manufacturing. Adjustments may be made to the production process based on, for example, the results of a batch made in a particular production environment.


Another exemplary formulation of a hair care product formulated to have non-comedogenic and/or non-acnegenic properties may be disclosed in table 2 and may be made by combining the following components in the proportions stated below. In an exemplary embodiment, the hair care product in table 2 may be used as a hair conditioner.









TABLE 2







Non-Comedogenic/Acnegenic Hair Conditioner Exemplary











Ingredient
Broad %
Preferred %













Part A
Water
50.0-90.0
60.0-90.0



Disodium EDTA
0.00-1.00
0.01-0.10



Phenoxyethanol
0.10-5.00
0.75-1.25



Ethylhexylglycerin
0.10-2.00
0.10-0.50



Citric acid
0.01-1.00
0.01-0.50



Stearamidopropyl dimethylamine
1.00-10.0
1.00-2.50



Polysorbate 80
0.00-5.00
0.10-1.00


Part B
Cetearyl alcohol
0.50-10.0
1.00-5.00



Behentrimonium chloride
0.10-5.00
0.50-3.00



Cetyl palmitate
0.50-5.00
1.00-4.00



C13-C15 alkane
0.50-15.0
2.00-7.00



Shea butter cetyl esters
0.10-8.00
0.50-2.00


Part C
Glycerin
0.00-10.0
0.10-2.00



Bisabolol
0.01-1.00
0.01-0.50



Fragrance
0.00-5.00
0.50-2.00









According to an exemplary embodiment, an exemplary hair care product formulation of table 2 may be prepared according to the following process or a process similar to the following. In a first step, a sanitized mixing vessel may be prepared, and a quantity of deionized water may be added to the sanitized mixing vessel. This DI water may then be heated to a temperature within the ranges of 80 to 85° C.


The remaining components of Part A may then be mixed into the mixing vessel. According to an exemplary embodiment, the remaining components of Part A may be added in an order or sequence, which may for example be the order in which they are shown in the table. In an exemplary embodiment, the ingredients may be added only once the previous ingredient has been fully dissolved. For example, in an exemplary embodiment, the phenoxyethanol of part A may be added, mixed until fully dissolved, and only then will the ethylhexylglycerin of part B be added.


The components of part B may be combined in a separate mixing vessel. According to an exemplary embodiment, the components of part B may be heated to a temperature in the range of 80 to 85° C. after combination, and may then be mixed until uniform.


The components of part B may then be combined with the components of part A, for example by adding the components of part B to the mixing vessel of part A. The resulting batch may then be mixed until it is smooth and uniform. The batch may then be cooled to a temperature within the range of 35 to 40° C.; according to an exemplary embodiment, mixing may be continued during this cooling process.


The ingredients of part C may then be added to the combined batch of parts A and B. According to an exemplary embodiment, ingredients may be added alone or in combination, as may be desired. The resulting batch may be mixed until uniform; following this, it may continue to be mixed and may be cooled (for example by ambient temperature) until the temperature of the batch reaches a temperature between 30 and 35° C.


The resulting composition may be a hair care product having the appearance of viscous cream. The color may be white to off-white, which may in some exemplary embodiments be adjusted if desired. The odor may be characteristic of the fragrance added to the composition; in some exemplary embodiments, the fragrance may be reduced or left out of the composition in order to produce an odorless composition. In an exemplary embodiment, the composition may have a pH at 25° C. of between 3.8 and 5.5 a viscosity at 25° C. (RVT), at spindle 5 at 20 rpm, of between 2000 and 30,000 cPs, and a specific gravity at 25° C. of between 0.98 and 1.03. In an exemplary embodiment, the composition may be kept to a low level of viable bacterial or fungal cells or other colony-forming units (CFU), of approximately <10 CFU/g; the composition may also be kept free of pathogens.


Another exemplary formulation of a hair care product formulated to have non-comedogenic and/or non-acnegenic properties may be disclosed in table 3 and may be made by combining the following components in the proportions stated below. In an exemplary embodiment, the hair care product in table 3 may be used as a curly styling cream.









TABLE 3







Non-Comedogenic/Acnegenic Curly


Styling Cream Exemplary Compositions











Ingredient
Broad %
Preferred %













Part A
Water
50.0-90.0
75.0-85.0



Disodium EDTA
0.00-1.00
0.05-0.20



Phenoxycthanol
0.10-5.00
0.75-1.25



Ethylhexylglycerin
0.10-2.00
0.10-0.50



Citric acid
0.01-1.00
0.01-0.50



Stearamidopropyl dimethylamine
1.00-10.0
1.00-2.50



Polysorbate 80
0.00-5.00
0.10-1.00


Part B
Cetearyl alcohol
0.50-10.0
1.00-5.00



Behentrimonium chloride
0.10-5.00
0.50-3.00



Squalene
0.00-8.00
0.50-5.00



C13-C15 alkane
0.50-15.0
1.00-5.00



Shea butter cetyl esters
0.10-8.00
0.50-5.00


Part C
Polyimide-1
0.00-3.00
0.10-1.00


Part D
Puricare ™ LS9727*
0.00-8.00
1.00-3.00



Bisabolol
0.01-1.00
0.01-1.00



Hydrolyzed Pea Protein
0.00-8.00
0.50-2.00



Keratrix ™**
0.00-10.0
1.50-4.50



Fragrance
0.00-5.00
0.01-2.00





 *Includcs water, glycerin, moringa Oleifera seed extract


**Includes water, glycerin, hydrolyzed ccratonia siliqua seed extract, zea mays starch, guar hydroxypropyltrimonium chloride, polyquaternium-7






According to an exemplary embodiment, an exemplary hair care product formulation of table 3 may be prepared according to the following process or a process similar to the following. In a sanitized mixing vessel, add disodium EDTA and water from Part A. Begin heating to 75-80° C. while mixing. Add remaining ingredients of Part A. Mix with heat until clear and all solids are dissolved. In a separate vessel, combine ingredients in Part B. Heat Part B to 75-80° C. and mix until uniform. Add Part B to Part A and mix until smooth and uniform. Add Part C to batch, mix until uniform and cool to 35-40° C. Add ingredients in Part D and mix until uniform. Continue mixing batch until temperate reaches 30-35° C. The product has the appearance of a white viscous cream with a pH@ 25° C.: 3.8-4.2; viscosity @ 25° C. (RVT): Spindle 5, 20 RPM 4,000-8,000 cPs; specific gravity @ 25° C.: 0.98-1.03; microbiology<10 CFU/g, No pathogens


Another exemplary formulation of a hair care product formulated to have non-comedogenic and/or non-acnegenic properties may be disclosed in table 4 and may be made by combining the following components in the proportions stated below. In an exemplary embodiment, the hair care product in table 4 may be used as a blow dry styling cream.









TABLE 4







Non-Comedogenic/Acnegenic Blow Dry


Styling Cream Exemplary Compositions











Ingredient
Broad %
Preferred %













Part A
Water
50.0-90.0
75.0-85.0



Disodium EDTA
0.00-1.00
0.05-0.20



Phenoxyethanol
0.10-5.00
0.75-1.25



Ethylhexylglycerin
0.10-2.00
0.10-0.50



Citric acid
0.01-1.00
0.01-0.50



Stearamidopropyl dimethylamine
1.00-10.0
1.00-2.50



Polysorbate 80
0.00-5.00
0.10-1.00


Part B
Cetearyl alcohol
1.00-5.00
1.00-5.00



Behentrimonium chloride
0.50-3.00
0.50-3.00



Squalene
0.50-5.00
0.50-5.00



C13-C15 alkane
1.00-5.00
1.00-5.00



Shea butter cetyl esters
0.50-5.00
0.50-5.00


Part C
Puricare ™ L59727
0.00-8.00
1.00-3.00



Bisabolol
0.01-1.00
0.01-1.00



Hydrolyzed Pea Protein
0.00-8.00
0.50-2.00



Keratrix ™
0.00-10.0
1.50-4.50



Fragrance
0.00-5.00
0.01-2.00









According to an exemplary embodiment, an exemplary hair care product formulation of table 4 may be prepared according to the following process or a process similar to the following.


In a sanitized mixing vessel, add disodium EDTA and water from Part A. Begin heating to 75-80° C. while mixing. Add remaining ingredients of Part A. Mix with heat until clear and all solids are dissolved. In a separate vessel, combine ingredients in Part B. Heat Part B to 75-80° C. and mix until uniform. Add Part B to Part A and mix until smooth and uniform. Continue mixing and cool to 35-40° C. Add ingredients in Part C and mix until uniform. Continue mixing batch until temperate reaches 30-35° C. The product has the appearance of a white viscous cream with a pH@ 25° C.: 3.8-4.2; viscosity @ 25° C. (RVT): Spindle 5, 20 RPM 3,000-8,000 cPs; specific gravity @ 25° C.: 0.98-1.03; microbiology<10 CFU/g, No pathogens


According to an exemplary embodiment, in a production environment, one or more small-scale batches, such as lab or pilot batches, may be made prior to large-scale manufacturing. Adjustments may be made to the production process based on, for example, the results of a batch made in a particular production environment.


Alternative compositions may also be envisioned, for example for other compositions of shampoos or conditioners or for other types of hair care products, such as styling gels or even combined shampoos and conditioners. For example, some embodiments may have relative compositions different from those shown; an exemplary composition may have a higher weight percent of one component chemical and a lower weight percent of a second component chemical. Equivalent or substantially equivalent component chemicals may also be substituted for chemicals within a composition. Appropriate substitutions may be appreciated by one of skill in the art.


The foregoing description and accompanying drawings illustrate the principles, preferred embodiments and modes of operation of the invention. However, the invention should not be construed as being limited to the particular embodiments discussed above. Additional variations of the embodiments discussed above will be appreciated by those skilled in the art.


Therefore, the above-described embodiments should be regarded as illustrative rather than restrictive. Accordingly, it should be appreciated that variations to those embodiments can be made by those skilled in the art without departing from the scope of the invention as defined by the following claims.

Claims
  • 1. A hair styling composition that does not have a tendency to block pores or cause acne, wherein the composition comprises: water, wherein the water is present in an amount between 50 and 90%;C13-C15 alkanes, wherein the C13-C15 alkanes are present in an amount from 0.5 to 15%;bisabolol, wherein the bisabolol is present in an amount between 0.01% and 1%;phenoxyethanol, wherein the phenoxyethanol is present in an amount between 0.1% and 5%; andcetearyl alcohol, wherein the cetearyl alcohol is present in an amount between 0.5% to 10.0%;behentrimonium chloride, wherein the behentrimonium chloride is present in an amount between 0.1% to 5.0%; anda combination of hydrolyzed ceratonia siliqua seed extract, zea mays starch, guar hydroxypropyltrimonium chloride, and polyquaternium-7,wherein the composition is a hair styling cream or a hair styling gel, andwherein the composition excludes parabens and sulfates.
  • 2. The composition of claim 1, wherein the composition further comprises disodium EDTA, ethylhexylglycerin, and citric acid.
  • 3. The composition of claim 2, wherein the disodium EDTA is present in an amount up to 1%.
  • 4. The composition of claim 2, wherein the ethylhexylglycerin is present in an amount up to 2.0%.
  • 5. The composition of claim 2, wherein the citric acid is present in an amount up to 1.0%.
  • 6. The composition of claim 1, wherein the composition further comprises glycerin and Moringa Oleifera Seed Extract.
  • 7. The composition of claim 1, wherein the composition further comprises a combination of glycerin and Moringa Oleifera Seed Extract, wherein the combination of said glycerin and said Moringa Oleifera Seed Extract is present in an amount up to 8%.
  • 8. The composition of claim 1, wherein the combination of said hydrolyzed ceratonia siliqua seed extract, said zea mays starch, said guar hydroxypropyltrimonium chloride, and said polyquaternium-7 is present in an amount up to 10%.
  • 9. The composition of claim 1, wherein the composition further comprises a combination of glycerin and Moringa Oleifera seed extract, wherein the combination of said glycerin and said Moringa Oleifera seed extract is present in an amount up to 8%, andwherein the combination of said hydrolyzed ceratonia siliqua seed extract, said zea mays starch, said guar hydroxypropyltrimonium chloride, and said polyquaternium-7 is present in an amount up to 10%.
  • 10. The composition of claim 1, wherein the composition further comprises shea butter cetyl esters.
  • 11. The composition of claim 1, wherein the composition further comprises shea butter cetyl esters, wherein the shea butter cetyl esters are present in an amount between 0.1 and 8.0%.
  • 12. The composition of claim 1, wherein the composition further comprises a fragrance in an amount up to 5.0%.
  • 13. A hair styling composition that does not have a tendency to block pores or cause acne, wherein the composition comprises: water, wherein the water is present in an amount between 50 and 90%;C13-C15 alkanes, wherein the C13-C15 alkanes are present in an amount from 0.5 to 15%;bisabolol, wherein the bisabolol is present in an amount between 0.01% and 1%;disodium EDTA, wherein the disodium EDTA is present in an amount up to 1%;phenoxyethanol, wherein the phenoxyethanol is present in an amount between 0.1% and 5%;ethylhexylglycerin, wherein the ethylhexylglycerin is present in an amount up to 2.0%;cetearyl alcohol, wherein the cetearyl alcohol is present in an amount between 0.5% to 10.0%;behentrimonium chloride, wherein the behentrimonium chloride is present in an amount between 0.1% to 5.0%;citric acid, wherein the citric acid is present in an amount up to 1.0%;a combination of glycerin and Moringa Oleifera Seed Extract, wherein the combination of said glycerin and said Moringa Oleifera Seed Extract is present in an amount up to 8%; anda combination of a hydrolyzed ceratonia siliqua seed extract, zea mays starch, guar hydroxypropyltrimonium chloride, and polyquaternium-7, wherein the combination of said hydrolyzed ceratonia siliqua seed extract, said zea mays starch, said guar hydroxypropyltrimonium chloride, and said polyquaternium-7 is present in an amount up to 10%.
  • 14. The composition of claim 13, wherein the composition excludes parabens and sulfates.
  • 15. The composition of claim 13, wherein the composition further comprises an additional polymer.
  • 16. The composition of claim 13, further comprising shea butter cetyl esters.
  • 17. The composition of claim 13, further comprising a fragrance.
CROSS REFERENCE TO RELATED APPLICATION

This application is a continuation of co-pending U.S. patent application Ser. No. 15/618,420, filed Jun. 9, 2017, which claims the benefit of Provisional U.S. Patent Application No. 62/348,510, filed Jun. 10, 2016, the entire contents and disclosure of which, both express and implied, are incorporated herein by reference.

US Referenced Citations (293)
Number Name Date Kind
5759527 Patel Jun 1998 A
5863546 Swinehart Jan 1999 A
6113891 Burdick et al. Sep 2000 A
6165493 Neurath et al. Dec 2000 A
6193986 Sakurada Feb 2001 B1
6268355 Mizobuchi et al. Jul 2001 B1
6281236 Farber Aug 2001 B1
6312675 Deane Nov 2001 B1
6350432 Modi Feb 2002 B1
6375975 Modi Apr 2002 B1
6406708 Karnerud et al. Jun 2002 B1
6436367 Modi Aug 2002 B1
6444213 Morita et al. Sep 2002 B1
6471954 Christensen Oct 2002 B2
6492326 Robinson et al. Dec 2002 B1
6649151 Barone et al. Nov 2003 B2
6673861 Tabacchi et al. Jan 2004 B2
6699464 Popp et al. Mar 2004 B1
6723309 Deane Apr 2004 B1
6723689 Hoang et al. Apr 2004 B1
6896897 Farber May 2005 B2
6923954 Doi et al. Aug 2005 B2
7078050 Fusco Jul 2006 B2
7182939 Tajima et al. Feb 2007 B2
7247173 Kleen et al. Jul 2007 B2
7262180 Mastrodonato et al. Aug 2007 B2
7294153 Kleen et al. Nov 2007 B2
7297717 Iwai et al. Nov 2007 B2
7314634 Hernandez et al. Jan 2008 B2
7326410 Doi et al. Feb 2008 B2
7393630 O'Hagan et al. Jul 2008 B2
7427407 Kume et al. Sep 2008 B2
7459166 Golz-Berner et al. Dec 2008 B2
7691792 Fisher et al. Apr 2010 B1
7744856 DeFilippi et al. Jun 2010 B2
7759332 Xu Jul 2010 B2
7763180 Tanaka et al. Jul 2010 B2
7807188 Hoath et al. Oct 2010 B2
7825207 Ferenz et al. Nov 2010 B2
7829067 D'Amelio, Sr. et al. Nov 2010 B2
7832413 Walters et al. Nov 2010 B2
7845360 Walters et al. Dec 2010 B2
7858840 Hisanaka Dec 2010 B2
7883729 Kohler et al. Feb 2011 B2
7901465 Chiba et al. Mar 2011 B2
7906557 Nishikawa et al. Mar 2011 B2
7956025 Copete Vidal et al. Jun 2011 B2
7959905 Axelrod et al. Jun 2011 B2
7959935 Hoath et al. Jun 2011 B2
8021674 Mateu et al. Sep 2011 B2
8088176 DeGeorge et al. Jan 2012 B2
8092813 Novicki Jan 2012 B1
8114475 Thomas Feb 2012 B2
8173143 Tecco et al. May 2012 B2
8183232 Inamoto et al. May 2012 B2
8206749 O'Hagan et al. Jun 2012 B1
8241681 Herrmann et al. Aug 2012 B2
8242169 Yoneda et al. Aug 2012 B2
8252298 Maderazzo et al. Aug 2012 B2
8309109 Tajima et al. Nov 2012 B2
8309143 Campbell et al. Nov 2012 B2
8337870 Kulesza Dec 2012 B2
8361520 Palmer Jan 2013 B2
8366688 Pesso Feb 2013 B2
8372383 Dascalu Feb 2013 B2
8476316 St. Laurent Jul 2013 B2
8506938 Lin Aug 2013 B2
8518424 Sasaki et al. Aug 2013 B2
8529925 Alexiades-Armenakas Sep 2013 B2
8562943 Klein Oct 2013 B2
8586111 Garris Nov 2013 B2
8586814 Fisher et al. Nov 2013 B2
8617579 Liu et al. Dec 2013 B2
8623330 Gurge et al. Jan 2014 B2
8628786 Novicki Jan 2014 B2
8642659 Springer et al. Feb 2014 B2
8697043 Ter-Antonyan et al. Apr 2014 B1
8703095 Klucker et al. Apr 2014 B2
8765158 Fukui et al. Jul 2014 B2
8808759 Barnes et al. Aug 2014 B1
8871190 Marshall et al. Oct 2014 B2
8906349 Schaeffer-Korbylo et al. Dec 2014 B2
8911774 Giampapa Dec 2014 B2
8957112 Mallard et al. Feb 2015 B2
9056065 Green-Tucker Jun 2015 B1
9101554 Sakuma Aug 2015 B2
9119974 Al-Qahtani Sep 2015 B2
9155915 Kunin Oct 2015 B2
9167839 Bezzek Oct 2015 B1
9180074 Fukui et al. Nov 2015 B2
9271956 Auclair Mar 2016 B2
9289495 Fossel Mar 2016 B2
9295622 Castro Mar 2016 B2
9295632 Benn et al. Mar 2016 B1
9303231 Patinier et al. Apr 2016 B2
9320744 Riepl Apr 2016 B2
9327021 Gallichan et al. May 2016 B2
9346722 Looten et al. May 2016 B2
9370570 Novicki Jun 2016 B2
9399009 Clark et al. Jul 2016 B1
9433564 Choi et al. Sep 2016 B2
9446089 Henderson Sep 2016 B1
9463158 Fossel Oct 2016 B2
9480634 Das et al. Nov 2016 B2
9498420 Laughlin, II et al. Nov 2016 B2
9504659 Klucker et al. Nov 2016 B2
9526681 Santarpia, III et al. Dec 2016 B2
9532969 Silver Jan 2017 B2
9539446 Schnider et al. Jan 2017 B2
9642795 Kiser et al. May 2017 B2
RE46441 Rueckl et al. Jun 2017 E
9744231 Klein Aug 2017 B2
9757317 Laughlin, II et al. Sep 2017 B2
9782333 Obias et al. Oct 2017 B2
9789042 Sasaki et al. Oct 2017 B2
9789099 Neufang et al. Oct 2017 B2
9801796 Pegard Oct 2017 B2
9801900 Gan et al. Oct 2017 B2
9822243 Malessa et al. Nov 2017 B2
9827176 Johnson Nov 2017 B2
9849071 Fack et al. Dec 2017 B2
9855346 Fang et al. Jan 2018 B2
20010053801 Tabacchi et al. Dec 2001 A1
20020048603 Burmeister et al. Apr 2002 A1
20020143063 Alvarado Oct 2002 A1
20020155083 Mann Oct 2002 A1
20020176876 Harris et al. Nov 2002 A1
20030003069 Carson et al. Jan 2003 A1
20030039619 Bunger et al. Feb 2003 A1
20030093045 Erdman May 2003 A1
20030102004 Hirata Jun 2003 A1
20030113315 Hirata et al. Jun 2003 A1
20030165585 Mann Sep 2003 A1
20030185920 Passi Oct 2003 A1
20040013618 Passi Jan 2004 A1
20040057917 Wolf et al. Mar 2004 A1
20040072915 Rougereau et al. Apr 2004 A1
20040185016 Popp et al. Sep 2004 A1
20040186042 Schmaus et al. Sep 2004 A1
20040258651 Pascaly et al. Dec 2004 A1
20040258652 Pascaly et al. Dec 2004 A1
20050008604 Schultz et al. Jan 2005 A1
20050025817 Bhatia et al. Feb 2005 A1
20050025847 Camus-Bablon et al. Feb 2005 A1
20050031571 Khaiat et al. Feb 2005 A1
20050074474 Sako Apr 2005 A1
20050089488 Kim Apr 2005 A1
20050152993 De Oliveira Jul 2005 A1
20050158262 Parris Jul 2005 A1
20050169865 Parris Aug 2005 A1
20050175646 Catroux et al. Aug 2005 A1
20050220810 Yano et al. Oct 2005 A1
20050226838 Krause et al. Oct 2005 A1
20050249761 Buenger et al. Nov 2005 A1
20050276767 Blin et al. Dec 2005 A1
20060024258 Fack et al. Feb 2006 A1
20060029627 Tsuchida et al. Feb 2006 A1
20060051310 Fack et al. Mar 2006 A1
20060051311 Walter et al. Mar 2006 A1
20060057075 Arkin et al. Mar 2006 A1
20060062749 Shelton et al. Mar 2006 A1
20070082017 Tseng Apr 2007 A1
20070082042 Park et al. Apr 2007 A1
20070087744 Haglund Apr 2007 A1
20070154439 Dorf Jul 2007 A1
20070166241 Baker Jul 2007 A1
20070243147 Wolber et al. Oct 2007 A1
20070264363 Bowen Nov 2007 A1
20070265353 Matsuhisa Nov 2007 A1
20070286838 Axelrod Dec 2007 A1
20070297992 Schiemann et al. Dec 2007 A1
20080015155 Mastrodonato et al. Jan 2008 A1
20080020004 Birkel et al. Jan 2008 A1
20080032384 Nomura Feb 2008 A1
20080057008 Naden et al. Mar 2008 A1
20080069898 Smith Mar 2008 A1
20080112898 Schiemann et al. May 2008 A1
20080171030 Jochim et al. Jul 2008 A1
20080175805 Schlemer Jul 2008 A1
20080175931 Schlemer et al. Jul 2008 A1
20080206371 Fontaine et al. Aug 2008 A1
20080275118 Shaw et al. Nov 2008 A1
20080305057 Fox Dec 2008 A1
20090074700 Nguyen et al. Mar 2009 A1
20090074888 Bhatia et al. Mar 2009 A1
20090098079 Schiemann Apr 2009 A1
20090130220 Johnson May 2009 A1
20090170816 Lacasa Mas et al. Jul 2009 A1
20090191136 Kroepke et al. Jul 2009 A1
20090226381 Maillefer et al. Sep 2009 A1
20100008880 Castro et al. Jan 2010 A1
20100074853 Gan et al. Mar 2010 A1
20100143512 Abdul-Malak et al. Jun 2010 A1
20100227008 Baker Sep 2010 A1
20100286102 Vielhaber Nov 2010 A1
20110112041 Schiffmann May 2011 A1
20110244063 Abdul-Malak et al. Oct 2011 A1
20110256249 Campbell Oct 2011 A1
20110305737 Alexiades-Armenakas Dec 2011 A1
20120082629 Türk Apr 2012 A1
20120093755 Humphreys Apr 2012 A1
20120128777 Keck et al. May 2012 A1
20120189684 Buckley et al. Jul 2012 A1
20120201857 Modi Aug 2012 A1
20120219605 Blackburn et al. Aug 2012 A1
20120263660 Altschul et al. Oct 2012 A1
20120283233 Gavin et al. Nov 2012 A1
20120289590 Ritterman et al. Nov 2012 A1
20120316144 Minobe Dec 2012 A1
20120321684 Maderazzo et al. Dec 2012 A1
20130005774 Loupenok Jan 2013 A1
20130079395 De Cupere et al. Mar 2013 A1
20130090279 Hilvert Apr 2013 A1
20130224268 Alam et al. Aug 2013 A1
20130231317 Riepl Sep 2013 A1
20130277307 Jensen et al. Oct 2013 A1
20140004176 Fossel Jan 2014 A1
20140004177 Fossel Jan 2014 A1
20140010866 Fossel Jan 2014 A1
20140037772 Lien Feb 2014 A1
20140154200 Lizarraga Jun 2014 A1
20140178478 Klucker et al. Jun 2014 A1
20140186284 Sha et al. Jul 2014 A1
20140187518 Kazin et al. Jul 2014 A1
20140271506 Laughlin, II et al. Sep 2014 A1
20140271923 Reid Sep 2014 A1
20140271940 Wurzer Sep 2014 A1
20140271949 Park et al. Sep 2014 A1
20140294921 Koverech et al. Oct 2014 A1
20140314911 Cheng Oct 2014 A1
20140348873 Banov Nov 2014 A1
20140350269 Eiji Borges Sato Nov 2014 A1
20150064122 Meyer et al. Mar 2015 A1
20150079175 Junior et al. Mar 2015 A1
20150080265 Elzinga et al. Mar 2015 A1
20150086522 Velez Mar 2015 A1
20150139929 Dixon May 2015 A1
20150157542 Schaeffer-Korbylo et al. Jun 2015 A1
20150174182 Agisim et al. Jun 2015 A1
20150177221 Peterson Jun 2015 A1
20150182447 Park Jul 2015 A1
20150182448 Yuan Jul 2015 A1
20150265526 Christensen Sep 2015 A1
20150297504 Botto Oct 2015 A1
20150352022 Laughlin, II et al. Dec 2015 A1
20150360183 Jensen et al. Dec 2015 A1
20160000682 Brooks et al. Jan 2016 A1
20160001099 Castro et al. Jan 2016 A1
20160008297 Schmaus et al. Jan 2016 A1
20160030553 Legon Feb 2016 A1
20160067181 Sawa Mar 2016 A1
20160081895 Elliott et al. Mar 2016 A1
20160151270 Brooks et al. Jun 2016 A1
20160175238 Shin et al. Jun 2016 A1
20160175432 Ma et al. Jun 2016 A1
20160200701 Berry et al. Jul 2016 A1
20160206573 Garcines et al. Jul 2016 A1
20160227776 Kawazu et al. Aug 2016 A1
20160250137 Noor et al. Sep 2016 A1
20160279073 Donsky et al. Sep 2016 A1
20160287484 Neame Oct 2016 A1
20160316750 Gries et al. Nov 2016 A1
20160317480 Brockman Nov 2016 A1
20160324754 Cure et al. Nov 2016 A1
20160324914 Compadre et al. Nov 2016 A1
20160330957 Quiroz et al. Nov 2016 A1
20160356798 Watkins Dec 2016 A1
20160367457 Mathis et al. Dec 2016 A1
20160374352 Modak et al. Dec 2016 A1
20160375136 Gavin et al. Dec 2016 A1
20170000707 Grevalcuore et al. Jan 2017 A1
20170014314 Alexandrova Jan 2017 A1
20170020807 Lutz et al. Jan 2017 A1
20170080084 Brito et al. Mar 2017 A1
20170096418 Patron Apr 2017 A1
20170119658 Turvey May 2017 A1
20170128355 Giampapa et al. May 2017 A1
20170128522 Gavaris May 2017 A1
20170209383 Gerchenson Jul 2017 A1
20170216177 Thrower Aug 2017 A1
20170216368 Moreno Gonzalez Aug 2017 A1
20170231895 Bae Aug 2017 A1
20170231899 Siddiqui Aug 2017 A1
20170266096 Kroon et al. Sep 2017 A1
20170266099 Kroon et al. Sep 2017 A1
20170273899 Kiser et al. Sep 2017 A1
20170281492 Dersh et al. Oct 2017 A1
20170281526 Dersh et al. Oct 2017 A1
20170281690 Moreno Gonzalez Oct 2017 A1
20170290799 Panin et al. Oct 2017 A1
20170348203 Schelges et al. Dec 2017 A1
20170354585 Rubin et al. Dec 2017 A1
20170368376 Yang et al. Dec 2017 A1
Foreign Referenced Citations (121)
Number Date Country
1097695 Sep 2002 EP
1140019 Jun 2003 EP
1061799 Apr 2004 EP
0947491 May 2004 EP
1000603 Feb 2005 EP
1077675 Aug 2005 EP
1222915 Sep 2005 EP
0978270 Feb 2006 EP
1493423 Jun 2006 EP
1252836 Aug 2006 EP
1192934 Oct 2006 EP
1566175 Oct 2006 EP
1152022 Feb 2007 EP
1410784 Feb 2007 EP
1353645 Sep 2007 EP
1629865 Oct 2008 EP
1816998 Mar 2009 EP
2090295 Aug 2009 EP
2029170 Oct 2009 EP
2218447 Aug 2010 EP
1576882 Oct 2010 EP
1116483 Dec 2010 EP
1778289 Jan 2011 EP
1014916 Jun 2011 EP
1696870 Sep 2011 EP
1937366 Dec 2011 EP
1581052 Jun 2012 EP
1693050 Jul 2012 EP
2120845 Oct 2012 EP
1370241 Nov 2012 EP
1545499 Feb 2013 EP
2214631 Apr 2013 EP
1627667 May 2013 EP
2649986 Oct 2013 EP
2650356 Oct 2013 EP
2662074 Nov 2013 EP
2145946 Jan 2014 EP
2155888 Jul 2014 EP
2179047 Jan 2015 EP
2839833 Feb 2015 EP
2842607 Mar 2015 EP
2529726 Jun 2015 EP
2878304 Jun 2015 EP
2700413 Oct 2015 EP
2065030 Nov 2015 EP
2977044 Jan 2016 EP
2464328 Mar 2016 EP
2604298 Mar 2016 EP
3015 114 May 2016 EP
3031322 Jun 2016 EP
1485066 Sep 2016 EP
2885004 Oct 2016 EP
2090296 Mar 2017 EP
3142633 Mar 2017 EP
3159044 Apr 2017 EP
2467120 May 2017 EP
3174519 Jun 2017 EP
2925412 Jul 2017 EP
3191074 Jul 2017 EP
2370052 Aug 2017 EP
2774601 Aug 2017 EP
2225003 Oct 2017 EP
2589693 Oct 2017 EP
3231414 Oct 2017 EP
2392311 Nov 2017 EP
2528577 Jan 2018 EP
WO 2005018629 Mar 2005 WO
WO 2010023559 Mar 2010 WO
WO 2010151240 Dec 2010 WO
WO 2011056226 May 2011 WO
WO 2011146837 Nov 2011 WO
WO 2011162954 Dec 2011 WO
WO 2012011904 Jan 2012 WO
WO 2012077120 Jun 2012 WO
WO 2012092528 Jul 2012 WO
WO 2012109152 Aug 2012 WO
WO 2013065051 May 2013 WO
WO 2013139808 Sep 2013 WO
WO 2013139812 Sep 2013 WO
WO 2014027370 Feb 2014 WO
WO 2014071354 May 2014 WO
WO 2014076533 May 2014 WO
WO 2014134620 Sep 2014 WO
WO 2014149867 Sep 2014 WO
WO 2014152382 Sep 2014 WO
WO 2014162280 Oct 2014 WO
WO 2014179520 Nov 2014 WO
WO 2015030702 Mar 2015 WO
WO 2015043931 Apr 2015 WO
WO 2015068052 May 2015 WO
WO 2015074667 May 2015 WO
WO 2015083174 Jun 2015 WO
WO 2015092609 Jun 2015 WO
WO 2015138479 Sep 2015 WO
WO 2015140138 Sep 2015 WO
WO 2015164290 Oct 2015 WO
WO 2015164433 Oct 2015 WO
WO 2015175333 Nov 2015 WO
WO 2016012110 Jan 2016 WO
WO 2016012587 Jan 2016 WO
WO 2016012757 Jan 2016 WO
WO 2016012797 Jan 2016 WO
WO 2016018315 Feb 2016 WO
WO 2016040757 Mar 2016 WO
WO 2016044374 Mar 2016 WO
WO 2016112201 Jul 2016 WO
WO 2016118907 Jul 2016 WO
WO 2016138505 Sep 2016 WO
WO 2016144675 Sep 2016 WO
WO 2016178660 Nov 2016 WO
WO 2016196989 Dec 2016 WO
WO 2017034384 Mar 2017 WO
WO 2017037534 Mar 2017 WO
WO 2017059136 Apr 2017 WO
WO 2017068505 Apr 2017 WO
WO 2017087924 May 2017 WO
WO 2017108902 Jun 2017 WO
WO 2017161036 Sep 2017 WO
WO 2017161387 Sep 2017 WO
WO 2017204618 Nov 2017 WO
WO 2018000060 Jan 2018 WO
Non-Patent Literature Citations (22)
Entry
Tash. “The complete List of Comedogenic Oils.” Holistic Health Herbalist. https://www.holistichealthherbalist.com/complete-list-of-comedogenic-oils/ accessed May 30, 2018, pp. 1-136. (Year: 2018).
A Leone, A Spada, A Battezzati, A Schiraldi, J Aristil, S Bertoli. “Moringa oleifera Seeds and Oil: Characteristics and Uses for Human Health.” International Journal of Molecular Sciences, vol. 17, 2016, pp. 1-14, published Dec. 20, 2016. (Year: 2016).
HS Nahm. “Quality Characteristics of West African Shea Butter (Vitellaria paradoxa) and Approaches to Extend Shelf-life.” Masters Thesis, Rutgers University. 2011. pp.: title page, i-xii, and 1-121. (Year: 2011).
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority dated Sep. 12, 2017, in connection with corresponding international application No. PCT/US2017/036745 (12 pgs.).
Kristin Collins Jackson, “3 Paraben and Sulfate Free Shampoos, Serums, and Body Washes to go Natural With This Summer”, article in bustle.com (http://www.bustle.com/articles/28720-3-paraben-and-sulfate-free-shampoos-serums-and-body-washes-to-go-natural-with-this-summer), Jun. 20, 2014, 7 pgs.
Lily Talakoub, “Smooth hair—an acne-causing epidemic,” Dermatology News, published Apr. 19, 2016, URL: http://www.mdedge.com/edermatologynews/article/108161/acne/smooth-hair-acne-causing-epidemic, 4 pgs.
Tina Ferraro, “Is Your Conditioner Causing You to Break Out?,” TeenVogue, published Jul. 3, 2015, URL: http://www.teenvogue.com/story/hair-conditioner-causing-acne-breakouts, 4 pgs.
Valerie Tejeda, “Are Your Hair Products Making You Break Out?,” TeenVogue, published Jul. 21, 2014, http://www.teenvogue.com/story/hair-products-cause-acne, 4 pgs.
Christa Joanna Lee, “How to Get Rid of Forehead Acne,” TeenVogue, published Jul. 12, 2016, URL: http://www.teenvogue.com/story/how-to-get-rid-of-forehead-acne, 4 pgs.
Carly Cardellino, “13 Surprising Reasons You Keep Breaking Out,” Cosmopolitan, published May 2, 2016, http://www.cosmopolitan.com/style-beauty/beauty/advice/a32686/surprising-things-that-cause-acne/, 12 pgs.
Lexy Lebsack, “The Annoying Reason You May Be Breaking Out,” Refinery29, published Jan. 9, 2016, URL: http://www.refinery29.com/hair-products-skin-break-outs, 16 pgs.
Porespective, “Five Causes of Adult Acne That May Surprise You,” Porespective, printed May 15, 2017, URL:https://www.porespective.com/five-causes-of-adult-acne-that-may-surprise-you/, 8 pgs.
Lauren Valenti, “The Sneaky Thing That's Making You Break Out . . . All Over,” MarieClaire, published Mar. 10, 2016, http://www.marieclaire.com/beauty/news/a19207/hair-products-skin-breakouts/, 8 pgs.
Kali Borovic, “12 Hair Mistakes That Cause Acne & Sabotage Your Best Skincare Efforts,” Bustle, published Mar. 5, 2016, URL: https://www.bustle.com/articles/146009-12-hair-mistakes-that-cause-acne-sabotage-your-best-skincare-efforts, 17 pgs.
Alexis C. Perkins, et al., “Acne Vulgaris in Women: Prevalence Across the Life Span,” 21 J Womens Health 223-230 (Feb. 2012), URL: http://online.liebertpub.com/toc/jwh/21/2, 9 pgs.
James Q. Del Rosso, et al., “Status Report From the American Acne & Rosacea Society on Medical Management of Acne in Adult Women, Part 1: Overview, Clinical Characteristics, and Laboratory Evaluation,” 96(4) Cutis 236-241, Oct. 2015, URL: http://www.cutis.com/uploads/media/media_1b35c69_CT096010236.PDF, 6 pgs.
American Academy of Dermatology, Acne: Overview, https://www.aad.org/public/diseases/acne-and-rosacea/acne visited Jun. 6, 2016, 3 pgs.
Nancy Janiczek-Dolphin, et al., “Can sebum reduction predict acne outcome?” 163(4) Br J Dermatol 683-8, Oct. 2010, URL: http//www.medscape.com/viewarticle/730258, 10 pgs.
Emil A. Tanghetti, “The Role of Inflammation in the Pathology of Acne,” 6 J Clinical and Aesthetic Dermatology, 27-35, Sep. 2013, 9 pgs.
Jamese . Fulton, Jr., “Comedogenicity and irritancy of commonly used ingredients in skin care products”, j. Soc. Cosmet. Chem., 40, 321-333, Nov./Dec. 1989, 13 pgs.
L Lanuza. “Sebamed Everyday Shampoo for Normal to Dry Hair and Scalp.” http://www.projectvanity.com/projectvanity/2011/10/27/sebamed-everyday-shampoo-for-normal-to-dry-hair-and-scalp.html, accessed Dec. 22, 2017, originally published Oct. 27, 2011, 8 printed pages. (Year: 2011).
HerbalLocks.com. “The Top 5 Non-Comedogenic Shampoos.” http://www.herballocks.com/natural-shampoos/top-5-comedogenic-shampoos/, accessed by examiner on Dec. 22, 2017, 10 printed pages. (Year: 2017).
Related Publications (1)
Number Date Country
20180235865 A1 Aug 2018 US
Provisional Applications (1)
Number Date Country
62348510 Jun 2016 US
Continuations (1)
Number Date Country
Parent 15618420 Jun 2017 US
Child 15957238 US